

November 05, 2022

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 023 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5 th Floor Plot No.C/1, 'G'Block, Bandra- Kurla Complex Bandra East Mumbai 400 051 Fax No.2659 8237/8238 Stock Code: ROSSARI
---	--

Dear Sir/Madam,

Subject: Q2 & FY23 Press Release

Please find enclosed a copy of the Press Release for the quarter ended September 30, 2022.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited

PARUL Digitally signed
by PARUL
GUPTA
GUPTA Date: 2022.11.05
22:43:39 +05'30'



Parul Gupta
Company Secretary & Compliance Officer
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai - 400078, India. **T** : +91-22-6123 3800 **F** : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. **T** : 0260-669 3000

: Plot No. D3/24/3, Opposite ATC Tyre Phase III, G.I.D.C Dahej, Village Galanda, Taluka Vagra, Bharuch-Gujarat - 392130, India. **T** : +91 2641-3505 03

info@rossari.com

www.rossari.com



Rossari Biotech Limited

Corporate Office: 201 A & B Ackruti Corporate Park LBS Marg Next to G. E. Gardens, Kanjurmarg West,
Mumbai, Maharashtra 400078

Rossari Biotech announces Q2 & H1 FY23 results

<u>Q2 FY23</u>	<u>H1 FY23</u>
Revenues at Rs. 425.4 Cr, higher by 11% YoY	Revenues at Rs. 860.1 Cr, higher by 40% YoY
EBITDA improves by 24% YoY to Rs. 56.6 Cr	EBITDA improve by 37% YoY to Rs. 114.3 Cr
PAT at Rs. 23.9 Cr, lower by 9% YoY	PAT at Rs. 52.6 Cr, higher by 4% YoY

Mumbai, November 05, 2022: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended September 30, 2022.

Consolidated: Q2 FY23 performance overview compared with Q1 FY23

- Revenues from operations stood at Rs. 425.4 crore as against Rs. 434.7 crore
- EBITDA at Rs. 56.6 crore as against Rs. 57.7 crore
 - EBITDA margin at 13.3% as against 13.3%
- PAT stood at Rs. 23.9 crore as against Rs. 28.7 crore
- EPS (Diluted) stood at Rs. 4.32 as against Rs. 5.18

Standalone: Q2 FY23 performance overview compared with Q1 FY23

- Revenues from operations stood at Rs. 240.9 crore as against Rs. 233.7 crore
- EBITDA at Rs. 27.9 crore as against Rs. 27.1 crore
 - EBITDA margin at 11.6% as against 11.6%
- PAT stood at Rs. 15.4 crore as against Rs. 15.4 crore
- EPS (Diluted) stood at Rs. 2.78 as against Rs. 2.78

Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said

“We have reported a steady performance in our key business segments during the quarter amidst a volatile operating environment. Our acquired companies performed consistently during the quarter. On a consolidated basis, our total revenue from operations stood at Rs. 425.4 crore in Q2 and 860.1 crore in H1.

In spite of continued challenging macro economic environment and subdued global demand, we have been able to maintain our Q –o- Q margins. On the raw material front we are now witnessing some price stability. This should help maintain our margins through the second half of the year.

During the quarter, we successfully acquired an additional 15% stake in Unitop and 8% in Tristar, taking our total holding to 80% and 84% respectively. Since the acquisition, both companies have added tremendous value to Rossari, and we are very pleased with the acquisitions and the seamless integration executed by our team.

Overall, we are optimistic that a stabilizing demand environment will drive sustainable growth in the upcoming quarters. To maintain our market position as a top provider of intelligent and sustainable solutions, our long-term focus will continue to be on growing our wallet share among our current client base while expanding out to emerging customer segments.

The Specialty Chemicals industry in India is fast progressing with strong growth prospects for the future. With a strong balance sheet, adequate manufacturing capacities and a diversified product portfolio, we are well-poised to capitalize on the upcoming opportunities in this space.”

Note:

- 1) All figures, unless mentioned otherwise, are on a consolidated basis
 - 2) EPS not annualized
 - 3) Rossari completed the acquisition of 65% equity shares of Unitop Chemicals Private Limited (“Unitop”) w.e.f August 26, 2021 and of 76% equity shares of Tristar Intermediates Private Limited (“Tristar”) w.e.f September 1, 2021. Accordingly, results for the quarter ended 30th September, 2022 and 30th June, 2022 includes results of Unitop and Tristar for the relevant periods, as applicable and hence the results for current quarter and quarter ended 30th September, 2021 (corresponding quarter) are not comparable.
-

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Manasi Nisal

Rossari Biotech Limited

Tel: +91 22 6123 3800

Email: manasi.nisal@rossari.com

Anoop Poojari / Aesha Shah

CDR India

Tel: +91 98330 90434 / 9867250569

Email: anoop@cdr-india.com /

aesha@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.